Emalex Biosciences Inc.
Clinical trials sponsored by Emalex Biosciences Inc., explained in plain language.
-
New drug ecopipam shows promise for Tourette's tics in Late-Stage trial
Disease control CompletedThis Phase 3 study tested whether ecopipam can safely maintain tic control in 216 people with Tourette's disorder, ages 6 and up. Participants first received open-label ecopipam, then those who responded were randomly switched to placebo or continued ecopipam to see if benefits l…
Phase: PHASE3 • Sponsor: Emalex Biosciences Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug shows promise for calming Tourette's tics in kids
Symptom relief CompletedThis study tested a drug called ecopipam in 40 children aged 7 to 17 with Tourette's syndrome. The goal was to see if it could reduce the frequency and severity of their motor and vocal tics. The drug works by blocking certain dopamine receptors in the brain. The main measure was…
Phase: PHASE2 • Sponsor: Emalex Biosciences Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC